Sanofi reports positive CHMP opinion in EU for once-daily Lyxumia (lixisenatide) for diabetes
Nov 16, 2012 (Menafn - M2 EQUITYBITES via COMTEX) --Healthcare company Sanofi SNY reported today that a positive opinion has been issued in Europe in favour of once-daily Lyxumia (lixisenatide).
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of once-daily Lyxumia for the treatment of adults with type 2 diabetes mellitus in order to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
This CHMP positive opinion will be forwarded to the European Commission, which has the authority to approve medicines for the European Union. Marketing authorisation is typically granted two to three months after a positive opinion.
Comments on this story may be sent to email@example.com
(C)1994-2012 M2 COMMUNICATIONS http://www.m2.com